MK-677 vs Ipamorelin: GH Secretagogue Research Comparison

MK-677 and Ipamorelin are both frequently searched under the umbrella of “growth hormone secretagogues” because each activates the same target: the growth hormone secretagogue receptor (GHSR-1a), better known as the ghrelin receptor. That shared endpoint is where the similarity ends. One is a long-acting, orally active non-peptide small molecule; the other is a short-acting injectable pentapeptide originally prized for its selectivity. Researchers, students of endocrinology, and readers auditing the peptide literature tend to compare the two when trying to understand how molecular form, half-life, and route of administration change the way a ghrelin-receptor agonist behaves.

This article sets MK-677 (ibutamoren, developer code MK-0677) and Ipamorelin (NNC 26-0161) side by side on mechanism, pharmacokinetics, development history, and the depth of published human evidence. The aim is descriptive: to characterize what each compound is and how it was studied, not to endorse use.

Research-only notice. MK-677 and Ipamorelin are investigational research compounds. Neither is approved by the FDA (or any comparable regulator) for human use, and both are handled as research chemicals. Nothing here is medical advice, dosing guidance, or a recommendation. This is an educational comparison of published scientific literature.

Mechanism of action

Both compounds converge on GHSR-1a in the hypothalamus and anterior pituitary, where receptor agonism amplifies growth-hormone-releasing-hormone signaling and blunts somatostatin tone, driving growth hormone (GH) release from pituitary somatotrophs. The downstream consequence of raised GH is increased hepatic secretion of insulin-like growth factor 1 (IGF-1). Because they share this pathway, they are often described as functionally similar. The pharmacology diverges in how that receptor is engaged and for how long.

Ipamorelin was introduced by Raun and colleagues in 1998 as “the first selective growth hormone secretagogue.” In vitro it released GH with an EC50 near 1.3 nmol/L and potency comparable to GHRP-6, but its defining feature was specificity: unlike the earlier peptides GHRP-6 and GHRP-2, Ipamorelin did not raise ACTH or cortisol above the levels seen with GHRH alone, and did not disturb prolactin, FSH, LH or TSH. That clean hormonal profile is the historical reason Ipamorelin is singled out among the GHRP peptides.

MK-677 is not a peptide at all. It is an orally bioavailable spiroindoline small molecule engineered to fit the ghrelin receptor with high (sub-nanomolar) affinity, acting as a ghrelin mimetic that amplifies GH pulsatility while raising both mean GH and IGF-1. Its practical distinction is durability: an elimination half-life on the order of 24 hours and roughly 60% oral bioavailability mean a single daily oral dose can hold IGF-1 elevated around the clock, whereas an injected pentapeptide such as Ipamorelin, with a terminal half-life near 2 hours, produces a single sharp GH pulse that decays quickly.

Evidence and development status

The two compounds are at very different depths of documentation. MK-677 carries the larger human dataset. The most cited study is Nass and colleagues’ 2008 randomized trial in the Annals of Internal Medicine: 65 healthy older adults took 25 mg of MK-677 or placebo daily, and over 12 months the compound raised 24-hour mean GH and IGF-1 into the range of healthy young adults, increased fat-free mass by about 1.5 kg, and was generally tolerated. Notably, the added fat-free mass did not translate into measured gains in strength or physical function, and fasting glucose rose while insulin sensitivity declined. MK-677 (as MK-0677) was also investigated by Merck across aging, Alzheimer’s disease, and hip-fracture recovery. A phase IIb hip-fracture trial (Adunsky et al., 2011) was stopped early after congestive heart failure occurred in 6.5% of the MK-0677 arm versus 1.7% on placebo, and the authors judged the safety profile unfavorable in that frail population. No sponsor has since advanced it through the FDA approval pathway.

Ipamorelin’s human record is thinner and older. Beyond the 1998 preclinical characterization, the key human paper is Gobburu and colleagues’ 1999 pharmacokinetic-pharmacodynamic modeling study in 40 healthy male volunteers, which established the roughly 2-hour half-life and the single-pulse GH response using intravenous infusion. Its furthest clinical reach was a phase II program run by Helsinn Therapeutics for postoperative ileus (impaired gut motility after abdominal surgery), a rational target given that ghrelin-receptor agonism is prokinetic. That program was discontinued after the trials did not establish efficacy, and Ipamorelin has not been evaluated in large pivotal human trials for any use. In short, MK-677 has been studied more extensively in people, including long-term, while Ipamorelin’s published human evidence is largely confined to short PK/PD work and an unsuccessful phase II indication.

Research context

The contexts in which the two appear reflect their pharmacology. MK-677 shows up in body-composition, sarcopenia, frailty, and IGF-1-axis research because oral dosing and a long half-life make sustained exposure practical to study, and because ghrelin agonism also touches appetite and sleep. Ipamorelin appears in work on selective GH stimulation, GH-axis dynamic modeling, and gastrointestinal motility, where its clean hormonal signature and short-lived pulse are analytically useful. The properties that make MK-677 convenient for chronic-exposure studies also concentrated its documented safety signals (glucose dysregulation, cardiac events in frail patients) into that longer-term human data, whereas Ipamorelin has not accumulated comparable long-term observation.

Key differences

• Molecular form: MK-677 is a non-peptide small molecule; Ipamorelin is a five-amino-acid peptide.
• Route: MK-677 is orally active; Ipamorelin, as a peptide, is administered parenterally in the studies that characterized it.
• Duration: MK-677’s ~24-hour half-life sustains IGF-1; Ipamorelin’s ~2-hour half-life yields a single transient GH pulse.
• Selectivity heritage: Ipamorelin was defined by GH selectivity (no ACTH/cortisol/prolactin rise); MK-677’s identity is oral durability and sustained IGF-1.
• Human evidence: MK-677 has multi-year randomized human data plus documented safety signals; Ipamorelin’s human evidence is short PK/PD work and a discontinued phase II indication.

Which for what research?

Framed strictly as research use rather than personal advice, the two suit different questions. A protocol examining sustained IGF-1 exposure, long-duration body-composition endpoints, or the practicality of oral ghrelin-receptor agonism aligns with MK-677’s profile and deeper human literature — while noting that its longer human record is also where glucose and cardiac safety signals appeared. A protocol focused on the acute, selective dynamics of GH release, dose-response modeling of a single GH pulse, or receptor selectivity without collateral ACTH/cortisol effects aligns with Ipamorelin’s characterized behavior. Neither is a validated therapeutic, and the evidence base for both remains investigational, so any comparison is about experimental fit and documented pharmacology, not clinical merit.

Put these side by side in the Compare Peptides tool.

Sources

• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID: 9849822
• Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. PMID: 10496658
• Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008. PMID: 18981485
• Adunsky A, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011. PMID: 21067829